• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Alvotech

    11/6/24 1:51:59 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALVO alert in real time by email
    SC 13G/A 1 tm2427411d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    AMENDMENT NO. 1 TO SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    Alvotech

    (Name of Issuer)

     

     

    Ordinary Shares, with nominal value of $0.01 per share

    (Title of Class of Securities)

     

    L01800108

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event, which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨       Rule 13d-1(b)

    x      Rule 13d-1(c)

    ¨       Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information, which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act out shall be subject to all other provisions of the Act, (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. L01800108

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
    YA II PN, Ltd.
    (98-0615462)
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Cayman Islands
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
         
    6 Shared Voting Power: 0
         
         
    7. Sole Dispositive Power: 0
         
         
    8. Shared Dispositive Power: 0
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:   0
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):        0%
         
      12. Type of Reporting Person (See Instructions):     OO

     

     

     

     

    CUSIP No. L01800108

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
    YA Global Investments II (U.S.), LP
         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Delaware
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
         
    6 Shared Voting Power: 0
         
         
    7. Sole Dispositive Power: 0
         
         
    8. Shared Dispositive Power: 0
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:  0
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         0%
         
      12. Type of Reporting Person (See Instructions):     OO

     

     

     

     

    CUSIP No. L01800108

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
    Yorkville Advisors Global, LP
       
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Delaware
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
         
    6 Shared Voting Power: 0
         
         
    7. Sole Dispositive Power: 0
         
         
    8. Shared Dispositive Power: 0
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:  0
         
      10. Check if the Aggregate Amount in Row (9)  Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         0%
         
      12. Type of Reporting Person (See Instructions):     OO

     

     

     

     

    CUSIP No. L01800108

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
    Yorkville Advisors Global II, LLC
         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Delaware
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
         
    6 Shared Voting Power: 0
         
         
    7. Sole Dispositive Power: 0
         
         
    8. Shared Dispositive Power: 0
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:   0
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         0%
         
      12. Type of Reporting Person (See Instructions):     OO

     

     

     

     

    CUSIP No. L01800108

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
    YAII GP, LP
         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Delaware
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
         
    6 Shared Voting Power: 0
         
         
    7. Sole Dispositive Power: 0
         
         
    8. Shared Dispositive Power: 0
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:   0
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         0%
         
      12. Type of Reporting Person (See Instructions):     OO

     

     

     

     

    CUSIP No. L01800108

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
    YAII GP II, LLC
         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Delaware
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
         
    6 Shared Voting Power: 0
         
         
    7. Sole Dispositive Power: 0
         
         
    8. Shared Dispositive Power: 0
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:   0
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         0%
         
      12. Type of Reporting Person (See Instructions):     OO

     

     

     

     

    CUSIP No. L01800108

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
    Mark Angelo
         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  United States
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
         
    6 Shared Voting Power: 0
         
         
    7. Sole Dispositive Power: 0
         
         
    8. Shared Dispositive Power: 0
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:  0
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         0%
         
      12. Type of Reporting Person (See Instructions):     OO

     

     

     

     

    CUSIP No. L01800108

     

      1. Names of Reporting Persons.
        I.R.S. Identification Nos. of above persons (entities only)
         
    SC-Sigma Global Partners, LP
    84-5173620
         
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  x
        (b)  ¨
         
      3. SEC Use Only
         
      4. Citizenship or Place of Organization:  Delaware
         

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With

    5. Sole Voting Power: 0
         
         
    6 Shared Voting Power: 0
         
         
    7. Sole Dispositive Power: 0
         
         
    8. Shared Dispositive Power: 0
         

      9. Aggregate Amount Beneficially Owned by Each Reporting Person:  0
         
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
         
      11. Percentage of Class Represented by Amount in Row (9):         0%
         
      12. Type of Reporting Person (See Instructions):     OO

     

     

     

     

    This Amendment No. 1 is being filed by YA II PN, Ltd., YA Global Investments II (U.S.), Ltd., Yorkville Advisors Global, LP, Yorkville Advisors Global II, LLC, YA II GP, LP, YAII GP II, LLC and SC-Sigma Global Partners, LP (collectively, the “Reporting Persons”) and amends, supplements and supersedes, the initial Schedule 13G filed jointly by the Reporting Persons on February 14, 2023. This Amendment No. 1 is the final amendment to the Schedule 13G and constitutes an exit filing for the Reporting Persons.

     

    Item 1.

     

      (a) Name of Issuer:

     

    Alvotech

     

      (b) Address of Issuer’s Principal Executive Offices:

     

    9, Rue de Bitbourg

    Luxembourg, Luxembourg L-1273

     

    Item 2. Identity and Background.

     

      (a) Name of Person Filing:

     

    YA II PN, Ltd.

     

      (b) Address of Principal Executive Office or, if none, Residence of Reporting Persons:

     

    1012 Springfield Ave.

    Mountainside, NJ 07092

     

      (c) Citizenship:

     

    Cayman Islands

     

      (d) Title of Class of Securities:

     

    Ordinary Shares, with nominal value of $0.01 per share

     

      (e) CUSIP Number:

     

    L01800108

     

    Item 3. If the statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is:

     

    (a) ¨  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b) ¨  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c) ¨  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d) ¨  Investment company registered under section 8 of the Investment Company Act of 1940 (15 of the Act (15 U.S.C. 78o);
    (e) ¨  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f) ¨  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g) ¨  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
    (h) ¨  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) ¨  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) ¨  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); or
    (k) x  Group, in accordance with 240.13d(b)(1)(ii)(K).

     

     

     

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

     

      (a) Amount beneficially owned: 0

     

      (b) Percentage of Class: 0%

     

      (c) Number of shares as to which the person has:

     

      (i) Sole Power to vote or to direct the vote: 0

     

      (ii) Shared power to vote or to direct the vote: 0

     

      (iii) Sole power to dispose or to direct the disposition: 0

     

      (iv) Shared power to dispose or to direct the disposition: 0

     

    Item 5. Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

     

    Item 6. Ownership of more than five percent on Behalf of Another Person.

     

    Not Applicable

     

     

     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not Applicable

     

    Item 8. Identification and Classification of Member Group

     

    YA II PN, Ltd. (“YA II”) is beneficially owned by YA Global Investments II (U.S.), LP (the “YA Feeder”). Yorkville Advisors Global, LP (the “YA Advisor”) is the investment manager to YA II. Yorkville Advisors Global II, LLC (the “YA Advisor GP”) is the general partner to the YA Advisor. YAII GP, LP (the “YA GP”) is the general partner to the YA Feeder. YAII GP II, LLC (the “Yorkville GP”) is the general partner to the YA GP. Mark Angelo makes the investment decisions on behalf of YA II. Accordingly, each of YA II, YA Feeder, the YA Advisor, the YA Advisor GP, the YA GP, the Yorkville GP and Mark Angelo may be deemed affiliates and therefore may be deemed to beneficially own the same number of Class A Shares.

     

    YAII GP, LP is the general partner of SC-Sigma Global Partners, LP (“SC-Sigma”), which is an investor in YA II. YAII GP II, LLC is the general partner of YAII GP, LP. The YA Advisor is the investment manager to SC-Sigma. Accordingly, SC-Sigma, the YA GP, the Yorkville GP, the YA Advisor, and Mark Angelo may be deemed affiliates and therefore may be deemed to beneficially own the same number of shares of Class A Shares. 

     

    For purposes of this filing, each of the reporting persons is deemed an affiliate of each other reporting person.

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable

     

    Item 10. Certification

     

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as participant in any transaction having that purpose or effect.

     

    Additional Information:

     

    Each Reporting Person disclaims beneficial ownership of any securities beneficially owned by each other Reporting Person, and its report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of these securities for the purpose of Section 16 or for any other purpose.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement in true, complete and correct.

     

      REPORTING PERSON:  
         
    Dated: November 6, 2024  
     
      REPORTING PERSON:
     
    YA II PN, Ltd.  
       
    By: /s/ Robert Munro  
      Robert Munro  
      Chief Compliance Officer  
       
    YA Global Investments II (U.S.), LP  
       
    By: /s/ Robert Munro  
      Robert Munro  
      Chief Compliance Officer  
       
    Yorkville Advisors Global, LP  
       
    By: Yorkville Advisors Global, LLC  
    Its: General Partner  
       
    By: /s/ Robert Munro  
      Robert Munro  
      Chief Compliance Officer  
       
    Yorkville Advisors Global II, LLC  
       
    By: /s/ Robert Munro  
      Robert Munro  
      Chief Compliance Officer  
       
    YAII GP, LP  
       
    By: YAII GP II, LLC  
    Its: General Partner  
       
    By: /s/ Robert Munro  
      Robert Munro  
      Chief Compliance Officer  

     

     

     

     

    YAII GP II, LLC  
       
    By: /s/ Robert Munro  
      Robert Munro  
      Chief Compliance Officer  

     

    SC-Sigma Global Partners, LP  
       
    By: /s/ Robert Munro  
      Robert Munro  
      Chief Compliance Officer  

     

     

     

    Get the next $ALVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALVO

    DatePrice TargetRatingAnalyst
    2/14/2025$18.00Buy
    UBS
    1/29/2024$10.00 → $17.00Equal Weight → Overweight
    Barclays
    10/20/2023$5.00 → $10.00Sell → Neutral
    Citigroup
    9/21/2023$10.00Equal Weight
    Barclays
    9/7/2022$10.00Equal-Weight
    Morgan Stanley
    9/6/2022$12.00 → $5.00Buy → Sell
    Citigroup
    More analyst ratings

    $ALVO
    Financials

    Live finance-specific insights

    See more
    • Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

      Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increaseProduct Revenues in the first in the first quarter of 2025 reached $109.9 million, compared to $12.4 million in the same period last year, representing a 786% increaseAdjusted EBITDA in the first quarter of 2025 was $20.5 million compared to negative $38.4 million in 2023Full year guidance increased to $600-$700 million in top line revenue and $200-280 million adjusted EBITDA, following acquisition of proposed biosimilar to CimziaAlvotech will conduct a business update conference call and live webcast on Thursday May 8, 2025, at 8:00 am ET (1

      5/7/25 4:45:00 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT

      REYKJAVIK, Iceland, May 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2025, after U.S. markets close on Wednesday, May 7, 2025. Alvotech will also conduct a conference call with analysts to present the financial results and recent business highlights on Thursday, May 8, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET).   Live audio of the conference call will be webcast and available to members of the news media, investors, and the general public. Information on how

      5/2/25 8:30:00 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech Reports Record Results for 2024 and Provides Business Update

      Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, representing a 462% increase over prior yearAdjusted EBITDA in 2024 was $108.3 million compared to negative $291 million in 2023Submissions in major global markets were made in 2024 for three new proposed biosimilars. All applications have been subsequently accepted by the relevant regulatory authorities.Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025, at 8:00 am ET (12:00pm GMT). REYKJAVIK, Iceland, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, or the "Company")), a global biotech company

      3/26/25 6:34:30 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Alvotech with a new price target

      UBS initiated coverage of Alvotech with a rating of Buy and set a new price target of $18.00

      2/14/25 9:00:38 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech upgraded by Barclays with a new price target

      Barclays upgraded Alvotech from Equal Weight to Overweight and set a new price target of $17.00 from $10.00 previously

      1/29/24 7:03:36 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech upgraded by Citigroup with a new price target

      Citigroup upgraded Alvotech from Sell to Neutral and set a new price target of $10.00 from $5.00 previously

      10/20/23 7:21:31 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVO
    Leadership Updates

    Live Leadership Updates

    See more
    • Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

      REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, or the "Company")), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Dr. Balaji V. Prasad as Chief Strategy Officer. A medical doctor by training, Dr. Prasad has 25 years' experience in the pharmaceutical industry, first as a consultant and subsequently as a financial and equities analyst focused on the specialty pharma and healthcare sectors. He was most recently a director and highly ranked equities analyst at Barclays, covering US specialty pharma and with Alvotech in his portfolio. He served previously

      3/27/25 4:30:00 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

      REYKJAVIK, Iceland and STOCKHOLM, March 20, 2025 (GLOBE NEWSWIRE) --  Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane Biopharma AB's ("Xbrane") R&D operations and a biosimilar candidate (the "Acquisition"), further expanding Alvotech's development capabilities, and establishing a footprint in the Swedish life science sector. The Acquisition includes Xbrane's R&D operations based in Campus Solna, at the Karolinska Institute outside Stockholm, Sweden, as well as the biosimilar candidate XB003, referencing Cimzia® (certolizumab pegol). Xbrane retains other

      3/20/25 3:00:00 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech Appoints Interim Chief Quality Officer

      REYKJAVIK, Iceland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Christina Siniscalchi will join its corporate leadership team as interim Chief Quality Officer. Christina succeeds Sandra Casaca, who is leaving the company as a part of other organizational changes. Christina Siniscalchi has for over ten years served in senior quality positions for Alvogen and its manufacturing site in Norwich, NY, most recently as Alvogen's Chief Quality Officer. "We thank Sandra for her valuable contribution to Alvotech, as she successfully steered ou

      2/29/24 4:05:00 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ALVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $ALVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ALVO
    SEC Filings

    See more
    • Amendment: SEC Form SC 13G/A filed by Alvotech

      SC 13G/A - Alvotech (0001898416) (Subject)

      11/6/24 1:51:59 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Alvotech

      SC 13D/A - Alvotech (0001898416) (Subject)

      7/3/24 5:31:12 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Alvotech (Amendment)

      SC 13G/A - Alvotech (0001898416) (Subject)

      2/14/24 12:14:38 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SELARSDI issued to ALVOTECH USA INC

      Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-2) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

      10/21/24 10:44:05 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SELARSDI issued to ALVOTECH USA INC

      Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-1) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

      10/21/24 2:59:28 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SELARSDI issued to ALVOTECH USA INC

      Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-3) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

      10/21/24 2:59:28 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

      Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increaseProduct Revenues in the first in the first quarter of 2025 reached $109.9 million, compared to $12.4 million in the same period last year, representing a 786% increaseAdjusted EBITDA in the first quarter of 2025 was $20.5 million compared to negative $38.4 million in 2023Full year guidance increased to $600-$700 million in top line revenue and $200-280 million adjusted EBITDA, following acquisition of proposed biosimilar to CimziaAlvotech will conduct a business update conference call and live webcast on Thursday May 8, 2025, at 8:00 am ET (1

      5/7/25 4:45:00 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025

      REYKJAVIK, Iceland, May 07, 2025 (GLOBE NEWSWIRE) --  Alvotech (NASDAQ:ALVO) (the "Company") a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the anticipated impact of potential tariffs on imported pharmaceuticals to the United States. Alvotech expects that potential U.S. tariffs on imported pharmaceuticals should have minimal impact on the Company's product revenues in 2025. Alvotech manufactures its biosimilars in Iceland, a country which currently faces the minimum tariff of 10% on goods imported to the U.S. A 10% tariff on pharmaceuticals would raise the cost of biosimilars from Alvotech

      5/7/25 5:00:00 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

      The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025SELARSDI is approved for all indications matching the reference productSELARSDI is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and pediatric patients 6 years and older, and the treatment of adult patients with moderately to severely active Crohn's disease and ulcerative colitis PARSIPPANY, N.J. and REYKJAVIK, Iceland, May 05, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutica

      5/5/25 7:00:00 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Alvotech

      6-K - Alvotech (0001898416) (Filer)

      5/8/25 6:00:33 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Alvotech

      6-K - Alvotech (0001898416) (Filer)

      5/7/25 11:58:42 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Alvotech

      6-K - Alvotech (0001898416) (Filer)

      5/5/25 8:00:06 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care